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The provision of effective Medical Countermeasures (MedCM) for all agents and routes of exposure is a
strategic goal of defence research and development. In the case of military autoinjector-based therapies
for nerve agent poisoning, current treatment effectiveness is limited by the oxime reactivator being
effective against only certain agents, by rapid clearance times of the drugs and because the doses may not
be optimal for treatment of severe poisoning. Prolonged poisoning by nerve agents entering the body
through the skin is also challenging. Since casualty handling timelines have reduced signiﬁcantly in
recent years, it may be sufﬁcient for ﬁrst aid therapy to provide protection for only a few hours until
further medical treatment is available. Therefore, the traditional evaluation of ﬁrst aid therapy in animal
models of survival at 24 h may not be appropriate. At various echelons of medical care, further thera-
peutic interventions are possible. The current basis for the medical management of nerve-agent poisoned
casualties is derived mainly from clinical experience with pesticide poisoning. Adjunct therapy with a
bioscavenger (such as human butyrylcholinesterase (huBChE)), could have utility as a delayed inter-
vention by reducing the toxic load. It has previously been demonstrated that huBChE is an effective post-
exposure therapy against percutaneous VX poisoning. It is recommended that the scope of animal
models of nerve agent MedCM are extended to cover evaluation of both ﬁrst aid MedCM over signiﬁ-
cantly reduced timescales, and subsequent supportive therapeutic and medical management strategies
over longer timescales. In addition to bioscavengers, these strategies could include repeated combined
and individual therapy drugs to alleviate symptoms, other classes of drugs or ventilatory support. Crown
Copyright © [2016] Published by Elsevier Ireland Ltd. This is an open access article under the Open
Government Licence (OGL) (http://www.nationalarchives.gov.uk/doc/open-government-licence/version/
3/).
Crown Copyright © 2016 Published by Elsevier Ireland Ltd. This is an open access article under the Open
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3/).1. Introduction
The Strategic Defence and Security Review of 2015 restated the
continuing risks faced by the UK including “Chemical and biological
attacks against the UK or its forces” which may become more likely
and/or have a greater impact over the longer term [1]. Although the




lsevier Ireland Ltd. This is an open
n/3/).likely than in the past, acquisition by non-state actors may be more
likely [2]. The continuing use of chemical agents like sarin and
chlorine in Syria [3] reinforces the requirement for effective ther-
apies to counter such highly toxic materials [4,5].
Organophosphorus compounds include pesticides and nerve
agents that act primarily by inhibiting the enzyme acetylcholines-
terase (AChE, E.C. 3.1.1.7). The primary routes of exposure to these
compounds are ingestion, inhalation and absorption through the
skin. AChE inhibition by anticholinesterase agents in both the pe-
ripheral and the central nervous system leads to an excess of the
neurotransmitter acetylcholine (ACh) in the synaptic cleft of
cholinergic synapses. Muscles, glands and nerves can become
overstimulated by excessive amounts of ACh, producing a range ofaccess article under the Open Government License (OGL) (http://www.nationa-
Table 1
Pharmacokinetic parameters of antidotal therapy drugs in humans.* parameter not
stated; derived from graphical data in Ref. [36].
Drug Dose & route of administration tmax t1/2 elim Reference
Atropine 2 mg, i.m. ~0.3 h* 2.34 h [36]
Diazepam avizafone 20 mg, i.m. 0.75 h 13.9 h [33]
Pralidoxime 700 mg, i.m. 0.63 h 2.94 h [34]
HI-6 500 mg, i.m. 0.69 h 1.15 h [35]
H. Rice et al. / Chemico-Biological Interactions 259 (2016) 175e181176toxic effects and ultimately death by loss of respiratory function [6].
Nerve agents are divided into two main groups, G agents and V
agents. G agents are more volatile, posing primarily an inhalation
hazard, whereas V agents, typiﬁed by VX, are more persistent, less
volatile and absorption through the skin represents a particularly
hazardous exposure route [7]. Exposure to airborne vapour causes
an acute cholinergic crisis that may develop within minutes of
exposure to nerve agent, and the resultant respiratory failure may
be fatal if not treated [8]. In contrast, percutaneous exposure to
nerve agents results in a slower onset of poisoning and an extended
exposure to toxic agent in the blood [9e12].
2. First aid medical countermeasures
Research into traditional nerve agent antidotal therapy has
historically been focussed on the military and has generally been
restricted to immediate self- and buddy-aid [13e24]. This is partly
because many exposure scenarios have concentrated on acute
(inhalation) poisoningwith volatile agents. Standard post-exposure
therapy for nerve agent toxicity consists of a muscarinic receptor
antagonist, usually atropine, combined with an AChE reactivator
(oxime), such as pralidoxime, obidoxime or HI-6. A benzodiazepine
anticonvulsant (usually diazepam or avizafone, a water-soluble
pro-drug which is converted in the body to diazepam) is the
usual treatment for control of seizures [7]. The therapy may be
supported by a pretreatment using a carbamate AChE inhibitor
(pyridostigmine), the action of which is to shield a proportion of
AChE from irreversible inhibition by nerve agent [25,26]. Military
therapeutic approaches are based on autoinjection devices to
enable immediate self- or “buddy”-aid in case of rapid develop-
ment of signs of poisoning [27].
Atropine is a broad-spectrum therapeutic, acting to competi-
tively displace ACh from muscarinic acetylcholine receptors. The
usual autoinjector dose (2 mg) was chosen to be the maximum
intramuscular dose compatible with military activities in the event
of an autoinjector being used in the absence of nerve agent
poisoning [28]. Similarly, the selection of the therapeutic dose of
avizafone was heavily inﬂuenced by the desire to reduce sedative
effects to a minimum following administration of one autoinjector.1
There is a synergistic relationship between atropine and avizafone,
and it has been shown that the requirement for avizafone/diaz-
epam can be reduced if the atropine dose is increased [29]. The
oxime dose2 was calculated from an animal toxic dose and human
safety and tolerability data, using a safety factor of 10 [30]. This dose
has been conﬁrmed as efﬁcacious based on animal studies [31],
though pralidoxime lacks the broad-spectrum effectiveness desir-
able to counter the complete range of threat agents [23,32].1 The doses are 10 mg avizafone in the UK Autoject (Combopen®) Nerve Agent
Antidote L4A1, up to 3 autoinjectors as required, or separate autoinjectors each
containing 10 mg diazepam in the US Convulsive Antidote, Nerve Agent (CANA)
device.
2 500 mg of pralidoxime methane sulphonate in a UK Combopen® or 600 mg of
pralidoxime chloride in the US Antidote Treatment Nerve Agent, Auto-Injector
(ATNAA).Following autoinjector administration, rapid absorption leads to
Tmax within 15e60 min for all drug components (Table 1) [33,34].
Atropine and pralidoxime in particular are rapidly eliminated, so
effective concentrations are maintained for a limited period only
[35e37]. An alternative oxime, HI-6, which is in development as a
replacement for pralidoxime in the UK MedCM, has similar phar-
macokinetic properties to pralidoxime (Table 1). Effective concen-
trations of diazepam are also only maintained for a limited period
[33].
The combination of these factors means that the issued auto-
injector therapies have some shortcomings in that limited protec-
tion is afforded against agents such as tabun, where the inhibited
AChE is resistant to reactivation by the oxime, and soman, where
the inhibited AChE ages rapidly. Moreover, relatively rapid clear-
ance of these ﬁrst aid therapies limits their effectiveness against
poisoning when agent exposure is by the percutaneous route
[23,38,39]. In these circumstances, it is very likely that additional
medical interventions will be needed to manage a nerve agent
casualty.
3. Bioscavengers
Stoichiometric bioscavengers are protein molecules that can
bind to nerve agents and prevent them from inhibiting central and
tissue cholinesterase. These have been widely investigated as a
novel, broad-spectrum nerve agent MedCM. For safety reasons,
human enzymes have been the preferred candidates, particularly if
the concept of use is administration as a pretreatment to healthy
(unpoisoned) individuals [40]. It has been shown that the stoi-
chiometric bioscavengers, human AChE and butyrylcholinesterase
(BChE, E.C. 3.1.1.8), provided substantial protection when adminis-
tered as a pretreatment against acute challenge by a range of nerve
agents in various animal species; for reviews see Lenz et al. [41],
and Nachon et al. [42]. There are, however, some disadvantages to
the large-scale pretreatment of individuals with signiﬁcant quan-
tities of protein. These include cost, possible immunogenicity and
the difﬁculties associated with pretreating at the appropriate time
relative to anticipated exposure to toxic agent.
In the case of percutaneous nerve agent poisoning, agent is
absorbed gradually from the site of contamination resulting in an
extended period over which toxic levels of nerve agent are present
in the body [9,12,43]. Although this means that there is potentially a
longer opportunity in which to administer post-exposure therapy,
it also presents a further challenge in that the therapymust provide
a long lasting protection. Although percutaneous VX poisoning can
be treated effectively with conventional MedCM, the survival
beneﬁt persists only as long as therapeutic levels of the drugs are
maintained. For example, Joosen et al. [10] found that, in guinea-
pigs, a single dose of atropine, obidoxime and diazepam, adminis-
tered at the appearance of ﬁrst signs of poisoning, extended the
period to detrimental physiological decline and death for several
hours. In contrast, repetitive administration of these drugs on the
reappearance of signs remained effective as long as treatment was
continued.
This indicates that repeated bolus application or, by inference,
continuous infusion of MedCM may protect for long enough that a
nerve agent-poisoned casualty could receive further treatment and
decontamination as part of the casualty handling chain, but this
approach is dependent on sufﬁcient access to supplies of MedCM.
An alternative approach would be to use a therapy in which the
protection afforded matched more effectively the time course of
poisoning. HuBChE has a long residence time in the blood and
better matches the toxicokinetics of a percutaneous nerve agent
exposure than the other MedCM components [44] (Fig. 1), meaning
that the circulating levels of a percutaneous nerve agent could be
Fig. 1. Composite diagram illustrating ﬁts to concentration-time proﬁles of atropine
(red line ¼ ﬁt to plasma atropine levels following i.m. atropine sulphate 17.4 mg kg1,
n ¼ 6) and huBChE (blue line ¼ ﬁt to plasma ChE levels following 3.4 mg kg1 huBChE
i.m., n ¼ 7) to guinea pigs, overlaid on a concentration-time proﬁle of VX in peripheral
muscle determined using microdialysis in guinea-pigs following percutaneous expo-
sure to VX (267.4 mg kg1) Redrawn from Ref. [46].
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previously demonstrated the efﬁcacy of huBChE as a post-exposure,
pre-symptomatic therapy and, when in combination with con-
ventional MedCM, as a post-exposure therapy when administered
on signs of poisoning following percutaneous exposure to VX in
guinea-pigs [44].
The protection factor afforded by one dose of conventional
MedCM (atropine 17.4 mg kg1, avizafone 3.14 mg kg1 and HI-6
27.9 mg kg1) in combination with huBChE (14,980 U kg1, i.m.),
administered on observable signs of cholinergic crisis following
percutaneous VX challenge, was 2.24 at 24 h (Price et al., unpub-
lished, Table 2). In contrast, without huBChE, the same MedCM
administered as three divided doses, on the appearance of signs of
poisoning and subsequently on worsening signs over a total dura-
tion of 6e9 h, were unable to protect guinea-pigs to 24 h against
2  LD50 of VX [45] and protected only 46% of animals to 24 h
against 1.2  LD50 VX (Rice and Price, unpublished observations).
These studies demonstrate that bioscavenger-based approaches
may have utility for treatment of percutaneous poisoning in post-
exposure settings. Early treatment may reduce the requirement
for conventional MedCM drugs and the prolonged period of pro-
tection may reduce the requirement for additional intensive med-
ical intervention and monitoring.
4. Military timescales for the medical management of nerve
agent-poisoned casualties
Within the military environment it is necessary to consider the
management of casualties in relation to the military medical chain
and in respect to the logistical burden of supplying treatment op-
tions at the various echelons. Recent experiences in militaryTable 2
LD50 values determined in guinea-pigs following percutaneous VX challenge. Saline con
poisoning (0.5e9 h, dose-dependent). No other medical intervention was given. Price et
Group LD50 mg kg1 95%
Control 613 551
huBChE þ atropine þ avizafone þ HI-6 1371 Indtheatres such as Afghanistan and Iraq have led to continuous
improvement in survival of combat casualties, as a consequence of
reduced timelines for evacuation coupled with further-forward
deployment of advanced life-saving technology and techniques
[47,48]. Penn-Barwell et al. attribute the improvement in outcome
to multiple factors, notably “a system that adopts an ‘‘end-to-end’’
approach, blurring the boundaries between point of wounding treat-
ment, prehospital en route care, receiving ﬁeld hospital management,
and in-ﬂight care during repatriation to continuing care in the Na-
tional Health Service” [47]. Although this statement is derived from
experience with conventional battleﬁeld injuries, a large fraction of
which were catastrophic trauma cases inwhich haemorrhagewas a
major cause of death [49], it is likely to be equally applicable to
chemical casualties.
The recognition that shortened casualty evacuation times and
the provision of more advanced medical care closer to the point of
injury has improved outcomes for survival also has implications for
the performance requirements for ﬁrst aid MedCM against chem-
ical agents. It suggests that these MedCM (self- or buddy-
administered autoinjectors) only need to be effective for the time
between the recognised “trigger to treat” and reaching further
medical support (Fig. 2). As with all ﬁrst aid, the purpose of this
initial drug therapy is to stabilise the casualty until more deﬁnitive
care can be given, the range and sophistication of which increases
through the echelons.
Treatment protocols for casualties who require continued sup-
portive therapy and monitoring following 3 autoinjectors are
generally based on clinical experience from organophosphorus
pesticide poisoning. The World Health Organisation (WHO) has
estimated an excess of 250,000 deaths annually from pesticide
poisoning worldwide, and a body of research exists on the treat-
ment [50]. Similarly, treatments used in the rare cases of human
nerve agent poisoning in, for example, the Iran-Iraq conﬂict in
1983e1988 [51] and theMatsumoto and Tokyo sarin attacks in 1994
[52e54], can inform recommendations [55], although the link be-
tween treatment and clinical outcome is often not reported clearly.
Atropine is regarded as the mainstay of treatment for OP
poisoning. In several clinical case reports the administration of
atropine is clearly associated with a reduction of cholinergic signs
and a favourable outcome [56]. Non-controlled (i.e. all patients
received atropine) clinical studies of OP-poisoned patients have
consistently described beneﬁcial effects of giving atropine, how-
ever there has been controversy concerning the optimal dose of
atropine [56,57]. In the Iran-Iraq war, atropine was almost exclu-
sively used as the supportive therapy for nerve agent-poisoned
casualties [51]. The atropine was titrated to effect, based on respi-
ratory status and pulse rate. In some cases of severe poisoning
doses of 20e200 mg were used [7]. Although the efﬁcacy of alter-
native antimuscarinic or antiglutamatergic agents (benactyzine,
scopolamine, gacyclidine and huperzine) has been demonstrated in
animal models of nerve agent poisoning, none have been evaluated
by high quality randomised clinical trials in humans [22,58e61]. It
has been suggested that benactyzine may be more suitable for
military personnel operating in high temperature environments
than atropine [55] because the inhibition of sweating is less than
that of atropine. Benactyzine is also more lipid-soluble than atro-
pine which may enhance CNS effects such as seizure termination.trol or therapy was administered i.m. on observable signs of systemic cholinergic
al., unpublished.
conﬁdence interval Slope estimate Protection ratio
e675 10.9
eterminate 49.23 2.24
Fig. 2. Timelines for nerve agent-poisoned casualties to reach different levels of medical care, based on the UK Armed Services protocols. I.M. intramuscular; I.O. intraosseous; I.V.
intravenous.
H. Rice et al. / Chemico-Biological Interactions 259 (2016) 175e181178For OP pesticide poisoning, the WHO has published a recom-
mendation to use oximes to treat all symptomatic patients who
need atropine [50]; however, the effectiveness of oximes in human
OP pesticide poisoning has been widely debated [23,50,55,62e66]and further evidence is needed to support dosing strategies. As is
the case for atropine, there are very limited reports of the use of
oximes in victims of nerve agent poisoning. Reports of the Matsu-
moto incident in Japan do not discuss the use of oximes; however,
H. Rice et al. / Chemico-Biological Interactions 259 (2016) 175e181 179pralidoxime methiodide (PAM) was used in the Tokyo incident and
was reported to be effective [53]. For the Iranian tabun and sarin
casualties, use of the limited supplies of obidoxime was reserved
for patients in critical condition and was restricted to emergency
units and ﬁeld hospitals. Although no data on clinical outcomes are
provided, it is implied that the treatment was successful: ‘reaction
was generally immediate and complete’ [51].
Benzodiazepines such as diazepam are the recommended an-
ticonvulsants for patients presenting with seizures and other CNS
symptoms. Although controlled studies in humans are lacking,
there is sufﬁcient evidence for efﬁcacy that it would in fact be
unethical to conduct a trial comparing a benzodiazepine with a
placebo [67]. Diazepam was used to treat victims of both the
Matsumoto and Tokyo sarin attacks, and was reported to control
convulsions and seizures [53]. Foroutan reported using diazepam
as an anticonvulsant as well as a muscle relaxant in the Iranian
casualties, but the incidence of seizures was not described [51].
Consideration should be given to the use of a bioscavenger such
as huBChE in higher echelon care by intravenous administration by
medically-trained personnel. For a number of reasons, deployment
at advanced medical care stations is more realistic than wider
availability for self-or buddy-aid. Although a lyophilised prepara-
tion is in development, present formulations require maintenance
of cold-chain storage to ensure stability of this protein. The high
cost of plasma-derived huBChE may also limit its availability [42]
and therefore targeted use in the medical management of these
casualties would enable more effective use of this limited resource.
An indication for the use of bioscavenger in medical management
of nerve agent poisoned casualties may be prolonged reliance on
conventional pharmacological medical management, which may
be indicative of percutaneous poisoning. In such cases bioscavenger
administration may reduce the circulating toxic load of nerve agent
in the body and reduce reliance on pharmacological therapy. A
similar concept of use has recently been discussed by Lockridge
[68], who reviewed three cases of organophosphorus pesticide
poisoning in which puriﬁed human plasma BChE was used.
Contaminated casualties may pose a risk to responders, so
hazard management will routinely include external and wound
decontamination. The requirement to decontaminate will depend
on the physical properties and persistency of the agent; removal of
clothing may be all that is required following vapour exposure to
non-persistent agent. In cases of percutaneous poisoning effective
decontamination would improve the clinical outcome of the nerve
agent casualty by limiting the dose received [69], but the detection
and decontamination of very small amounts of highly toxic mate-
rial will be challenging. Decontamination of liquid agent may
involve dry or wet decontamination. Dry decontamination relies on
adsorption of liquid contaminant by powders (e.g. Fuller’s Earth,
M291 skin decontamination kit). Bleach solution (0.5% aqueous
sodium hypochlorite), reactive decontamination products (e.g.
RSDL) or copious amounts of water can be used for wet decon-
tamination [69,70]. Depending on the particular operation, the
decontamination of the casualty could occur before or after initial
evacuation, but should not interrupt or delay medical treatment
[71]. There may be a requirement to carry out life-saving in-
terventions before any decontamination takes place.
5. Animal models of ﬁrst aid and medical management
The guinea-pig is widely used as a small animal model for proof-
of-principle MedCM studies to OP poisoning. Non-human primates
or pigs are considered appropriatemodels for pivotal efﬁcacy studies
[20,26,72e76]. Each species has advantages and disadvantages that
need to be considered in the interpretation of results and extrapo-
lation to man [20,77e79]. Animal studies of nerve agent MedCMefﬁcacy have conventionally used survival at 24 h as an end-point
[16,17,59,80,81]. In these studies, treatment provided good protec-
tion from acute nerve agent poisoning, but in some groupsmortality
increased sharply between 4 h and 24 h. An earlier end-point which
is based on likely casualty processing times (e.g. 4e6 h) would be
more appropriate for identifying effective ﬁrst aid MedCM and
would be less likely to exclude useful treatments that have a short
duration of effectiveness. Assessment of the integration of ﬁrst aid
therapy with supportive medical care has not been undertaken. Pigs
have been used in experimental treatment studies for injury caused
by other toxic chemicals [82e87], but less extensively in nerve agent
therapy evaluation [88e90]. There are research studies in pigs and
clinical trials information for treatment strategies following organ-
ophosphate pesticide poisoning. Typically these studies and clinical
cases involve ingestion of the OP and therefore result in a delayed
onset of signs and symptoms of poisoning. This is similar to that
observed following percutaneous nerve agent poisoning [50,91e93].
The adaptation of these pig models to assess both ﬁrst aid and
continuedmedicalmanagement could be used to further investigate
the utility of huBChE as a delayed, post-exposure therapeutic inter-
vention. Other therapeutic strategies that could be explored in the
model include, for example, novel reactivators (oximes) [94,95],
anticonvulsants [59,96], antinicotinics [97,98], GABA- or glutamate
antagonists [99e101] and neuroprotectants [102].
6. Conclusions
It is likely that following any exposure to nerve agents in a
military environment a combination of ﬁrst aid and further medical
interventionwould be required; this is particularly relevant in cases
of nerve agent absorbed by the percutaneous route. Research into
medical countermeasures has previously focussed primarily on ﬁrst
aid interventions for nerve agent poisoning. We suggest that there
is a requirement to extend the scope of current therapeutic in-
terventions for nerve agent poisoning in animal models to
encompass continued management of the “casualty” through the
medical chain. This has implications for the animal models in use,
and also the time points for both intervention and assessment of
efﬁcacy. The timescales for evaluation of ﬁrst aid therapy should
reﬂect the realistic duration over which therapy is expected to be
effective. Subsequent therapeutic interventions should reﬂect the
capabilities available at the various levels of medical care. It is
proposed that bioscavengers such as huBChEmay have utility in the
medical management of nerve agent-poisoned casualties. This is
primarily as an adjunct to other drug-based, or other therapeutic
interventions. In particular, the use of bioscavengers has particular
relevance to the treatment of percutaneous nerve agent poisoning.
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